0001209191-18-009631.txt : 20180213 0001209191-18-009631.hdr.sgml : 20180213 20180213170450 ACCESSION NUMBER: 0001209191-18-009631 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180209 FILED AS OF DATE: 20180213 DATE AS OF CHANGE: 20180213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bazemore Robert B CENTRAL INDEX KEY: 0001620152 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35945 FILM NUMBER: 18604626 MAIL ADDRESS: STREET 1: 33 HAYDEN AVE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Epizyme, Inc. CENTRAL INDEX KEY: 0001571498 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261349956 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-229-5872 MAIL ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-09 0 0001571498 Epizyme, Inc. EPZM 0001620152 Bazemore Robert B C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 1 0 0 President & CEO Stock Option (Right to Buy) 16.00 2018-02-09 4 A 0 265860 0.00 A 2028-02-08 Common Stock 265860 265860 D This option was granted on February 9, 2018 pursuant to the Company's 2013 Stock Incentive Plan with respect to 265,860 shares of Common Stock, with 25% vesting on February 9, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. /s/ Adriana Sullivan, attorney-in-fact 2018-02-13